J&J: flat and lifeless? | IBM's Deep Blue beat |
Finimize

Hi John, here's what you need to know for January 23rd in 3:10 minutes.

🎩 Our finance community will become the world’s biggest in 2020, and we’re looking to get you involved as we make history. First up, we need people to organize events on the futures of venture capital, sustainable investing, and tech stocks. Get involved

Today's big stories

  1. Healthcare and consumer giant Johnson & Johnson reported fourth-quarter sales that fell short of investors' expectations
  2. Coutts, the go-to bank for Britain’s 0.1%, is bullish on markets in 2020 – Read Now
  3. IBM’s earnings were better than expected, but appearances might be deceiving this earnings season
1/3

Washout

Washout

What’s Going On Here?

Investors weren't left feeling particularly fresh on Wednesday after global healthcare and consumer products giant Johnson & Johnson (J&J) Suda-fed them fourth-quarter sales that fell short of expectations.

What Does This Mean?

J&J’s global sales across 2019 ended essentially flat on the year before. While pharmaceuticals revenue climbed almost 4%, this was largely offset by a similar decline in medical device sales. Even J&J’s large consumer business – featuring brands such as Neutrogena beauty products and Tylenol painkillers – couldn’t save the day: sales of those products barely budged last year compared to 2018.

The company seems more optimistic about this year, telling investors it expects 4-5% sales growth in 2020 despite the increasing threat posed by generic unbranded drugs to its pharmaceutical business, which represents half of total revenue. But there’s another catch: that sales growth depends on J&J’s current legal headaches getting resolved favorably. Time for a Tylenol, perhaps?

Why Should I Care?

For you personally: Defensive pass interference. 
Investors are attracted to the “defensive” qualities of companies like J&J: even if the economy heads south, sales of their essential products should stay resilient. But the world’s largest healthcare company is currently working on a defensive play of its own: J&J is facing thousands of lawsuits covering everything from potentially carcinogenic talcum powder to potentially carcinogenic Tylenol. On second thoughts...

Zooming out: Abbott and beyond. 
While J&J’s share price fell on Wednesday, healthcare investors did have one reason to rejoice: fellow US pharmaceutical and medical device giant Abbott Labs saw its stock rise after the company reported quarterly sales ahead of investors' expectations, and forecast continuing momentum this year. Investors liked the sound of that, and may also be drooling over the company’s potential to provide them with income of their own: Abbott increased its dividend last month by 12.5%, marking the 48th consecutive year of dividend growth.

Copy to share story: https://www.finimize.com/wp/news/washout/

2/3 Premium Story

Coutts Moots

The economy and markets are entering a bright patch, says a report from Coutts – the 327-year-old private bank that manages money for the Queen. And to get its clients ready for the good times, it’s starting to move their investments elsewhere…

Get the full story in the Finimize app

3/3

Chin Up

Chin Up

What’s Going On Here?

Computing giant IBM’s fierce financials saw its stock price rise 3% on Wednesday, and it isn’t the only stunner on the catwalk. But are positive surprises really so in fashion this earnings season?

What Does This Mean?

IBM’s revenue grew (just) last quarter compared to a year before, thanks to a new mainframe model and strong software sales from a trendy Red Hat. That was a relief for investors who’d dealt with falling revenue for the previous five quarters.

Overall, 72% of US companies reporting fourth-quarter earnings so far have flaunted better-than-expected profits. That’s in line with the five-year average: companies prefer to underpromise and overdeliver. Appearances can be deceptive, however. These earnings have only been 1.1% better than expected on average, compared to a 4.9% average beat over the last five years.

Why Should I Care?

For markets: Waning energy.
Pleasant surprises are always more likely when expectations are low – and investors’ are lowering still. Across the US stock market, analysts now expect last quarter’s earnings to come in 2.1% lower than in 2018, compared to 1.5% at the start of January. Pessimism is principally pumping from the energy sector, where profits are expected to drop more than 40% from a year before. A low oil price and increasing costs have already hurt support firms like Baker Hughes, with all eyes now on US production giants Chevron and ExxonMobil’s earnings next Friday.

The bigger picture: Who will buy?
The low oil price is partly due to a general economic slowdown that’s also taking a big bite out of consumer discretionary companies: firms that make goods people want, but don’t need. The sector’s overall fourth-quarter profits are expected to end up 14% lower than in 2018, but there may be hope in store: luxury retailer Burberry raised its profit outlook on Wednesday thanks to particularly strong performance in China last quarter. Nevertheless, the rise of a deadly virus in the country could yet dampen consumer demand...

Copy to share story: https://www.finimize.com/wp/news/chin-up/

💬 Quote of the day

“Remember when life’s path is steep to keep your mind even.”

– Horace (a leading Roman lyric poet)
Tweet this

#chartoftheweek

🌱 From cash to climate change, green is the only color Davos’s big-hitters care about

23012020---COTW

Do your bit: share this chart

⚡️ Lightning insight

Saudi Aramco produces 410 million gallons of oil each day: 10% of the entire world’s supply.

Even as the debate around climate change swirls among the uber-rich at Davos, oil producer Saudi Aramco is sitting pretty after staging the biggest ever initial public offering. But renewables are gradually becoming more cost-effective, and our analysts have dug into what’ll happen if that puts Aramco’s bread and butter at risk. Read our Pack now

📚 What we're reading

❤️ Share with a friendYour Referrals: 0

Thanks for reading, John. If you liked today's brief, we'd love for you to share it with a friend. If they sign up on your unique link, you’ll earn some sweet swag.

Share your unique link:

https://finimize.com/invite/?kid=12T6MV

You stay classy, John 😉

Image Credits:

Image credits: Firdaus Khaled - Shutterstock | Robuns - Shutterstock, Hilbrand Bos Illustrator @hilbrandbos - Giphy

Preferences:

Change your edition or update your email

View in browser

Unsubscribe from all Finimize Emails

😴

Crafted by Finimize Ltd. | Third Floor, 1 New Fetter Lane, London, EC4A 1AN, UK.

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2020